JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences (NASDAQ:GILD) had its target price increased by equities researchers at JPMorgan Chase & Co. from $150.00 to $160.00 in a note issued to investors on Wednesday,MarketScreener reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 5.39% from the company’s current price.

A number of other research firms have also recently commented on GILD. Leerink Partners boosted their price target on Gilead Sciences from $114.00 to $146.00 and gave the stock an “outperform” rating in a report on Friday, January 30th. Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $100.00 to $103.00 and gave the company a “sector perform” rating in a research report on Tuesday, January 20th. Sanford C. Bernstein set a $135.00 target price on shares of Gilead Sciences and gave the stock an “outperform” rating in a research report on Monday, December 29th. Daiwa Securities Group raised their target price on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. Finally, Wall Street Zen downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Twenty-three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $152.42.

Gilead Sciences Trading Down 2.6%

Shares of Gilead Sciences stock opened at $151.81 on Wednesday. Gilead Sciences has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.68. The company has a market capitalization of $188.35 billion, a P/E ratio of 22.42, a P/E/G ratio of 0.81 and a beta of 0.36. The company has a fifty day moving average of $129.59 and a 200 day moving average of $121.98.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same period last year, the firm earned $1.90 earnings per share. The business’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, sell-side analysts anticipate that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the transaction, the insider owned 103,221 shares of the company’s stock, valued at approximately $12,831,402.51. This trade represents a 2.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the transaction, the chief financial officer owned 150,503 shares of the company’s stock, valued at approximately $18,709,027.93. This represents a 1.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 319,391 shares of company stock worth $44,141,101. 0.27% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Gilead Sciences

Several large investors have recently modified their holdings of the stock. Brighton Jones LLC raised its stake in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,450 shares during the period. Bison Wealth LLC purchased a new position in shares of Gilead Sciences during the 4th quarter worth about $215,000. Sivia Capital Partners LLC grew its holdings in Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after purchasing an additional 602 shares during the last quarter. Vest Financial LLC raised its position in Gilead Sciences by 39.3% in the 2nd quarter. Vest Financial LLC now owns 14,472 shares of the biopharmaceutical company’s stock worth $1,605,000 after purchasing an additional 4,080 shares during the period. Finally, Cornerstone Wealth Group LLC raised its position in Gilead Sciences by 20.1% in the 2nd quarter. Cornerstone Wealth Group LLC now owns 2,822 shares of the biopharmaceutical company’s stock worth $313,000 after purchasing an additional 472 shares during the period. Institutional investors own 83.67% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 results beat consensus — revenue and EPS topped estimates, driven by HIV and liver‑disease portfolio strength and early traction for new products; this underpins analyst bullishness and longer‑term revenue visibility. GILD’s Q4 Earnings Beat
• Positive Sentiment: Big wave of analyst price‑target increases and buy/outperform notes (examples: Morgan Stanley $171, Scotiabank $177, Needham/Wolfe $170, Wells Fargo & JPMorgan mid‑$160s) — brokers cite HIV momentum, margin expansion and product pipeline (Yeztugo, Yescarta) as reasons to raise targets. Analyst Coverage Summary
• Positive Sentiment: Dividend increase announced — quarterly dividend up to $0.82 (3.8% raise), supporting income investor appeal and signaling management confidence in cash flow.
• Neutral Sentiment: Earnings call / transcripts published (multiple outlets) — useful for detail on guidance assumptions, product rollouts and cost/margin outlook but neutral until investors parse management commentary. Earnings Call Transcript
• Neutral Sentiment: Yescarta label expansion and new product commentary appear in coverage — potential medium‑term upside if uptake meets expectations; currently a pipeline/progression read‑through. Yescarta & Dividend Coverage
• Neutral Sentiment: Short‑interest notes in data feeds show anomalous 0 shares / NaN changes — not meaningful evidence of a short squeeze or new bearish positioning based on available figures.
• Negative Sentiment: FY‑2026 guidance came in below some Street expectations — management’s outlook tempered the post‑earnings rally and is the principal reason for the intraday/extended‑session pullback despite the beat. Guidance / Shares Dip
• Negative Sentiment: At least one broker adjustment (Royal Bank of Canada) shows a lower relative price target in published feeds despite a PT raise vs. prior internal note — highlights disagreement among analysts on near‑term valuation and reinforces guidance‑driven uncertainty. RBC / Ticker Report

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.